Developing countries need better antiretroviral drugs.
Mykén
Nanna
N
Sundbeck
Boel
B
Mpumilwa
Godfrey
G
Andersson
Rune
R
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003906:Developing Countries; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000009:adverse effects / Q000627:therapeutic use*; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use*; D013636:Tanzania / Q000453:epidemiology; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine